ProKidney Corp. (PROK)
PROK trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/0001193125-26-113881-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PROK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001850270 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | E9 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $893K |
| Net income | -$69.0M |
| Operating income | -$165.0M |
| Net margin | -7725.2% |
| Operating margin | -18477.8% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $108.5M |
| Total assets | $335.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 531.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2025-10-21 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-08-10 |
| Latest current report | 8-K | 2026-08-10 |
| Latest proxy | DEFA14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 397 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.0% |
| 1 month | -17.0% |
| 3 months | -10.2% |
| Year to date | -35.5% |
| 1 year | -51.7% |
| From 52-week high | -56.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $7.26 | -6.56% | $479.3M |
| ALLO | Allogene Therapeutics Inc. | $1.29 | -7.86% | $445.7M |
| AGMB | AgomAb Therapeutics NV | $8.81 | -3.08% | $433.9M |
| ENTX | Entera Bio Ltd. | $2.49 | -6.04% | $433.1M |
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.62 | -6.90% | $431.2M |
| VALN | Valneva SE | $5.56 | -6.24% | $527.6M |
| DBVT | DBV Technologies S.A. | $9.03 | -5.45% | $534.7M |
| ETRA | Electra Therapeutics Inc. | $8.61 | -7.62% | $540.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier